Literature DB >> 10779297

Interleukin-8 is a chemo-attractant for eosinophils purified from subjects with a blood eosinophilia but not from normal healthy subjects.

R Sehmi1, O Cromwell, A J Wardlaw, R Moqbel, A B Kay.   

Abstract

Interleukin-8 (IL-8), a pro-inflammatory cytokine with potent neutrophil chemotactic activity, was studied for its effect on eosinophil migration responses, in vitro. Normal density eosinophils were isolated from healthy, non-atopic subjects (<0.35 x 10(9) eosinophils/l) and individuals with various diseases associated with a blood eosinophilia (range 0.56 x 10(9)-12.2 x 10(9) eosinophils/l). IL-8 produced a dose-dependent migrational response for eosinophils from subjects with an eosinophilia, optimal at 10(-8) M (P < 0.01) and the major component of the migrational response was chemokinesis. On a molar basis, IL-8 (EC50 approximately 10(10) M) was 100-fold more potent than platelet activating factor (PAF), although a comparison of the migrational responses showed that at optimal concentrations IL-8 (10(-8) M) produced only 30% maximal responses stimulated by PAF (10(-6) M). In contrast, IL-8 tested over a wide concentration range had a negligible effect on eosinophils from normal subjects. A direct correlation between the total blood eosinophil counts for all subjects and the absolute magnitude of the migrational response to IL-8 (r = 0.727, P < 0.01 at 10(-8) M), PAF (r = 0.551, P < 0.03 at 10(-6) M) and N-formyl-methionyl-leucyl-phenylalanine (fMLP) (r = 0.689, P < 0.02 at 10(-8) M), suggested that heightened eosinophil migrational responses to inflammatory mediators may arise as a consequence of in vivo priming mechanism(s) associated with the development of an eosinophilia. In this regard, eosinophils derived from human cord blood mononuclear cells cultured in the presence of eosinophilopoietic cytokines IL-3 and IL-5, produced migrational responses to IL-8 and PAF, that were comparable with that of eosinophils from eosinophilic subjects. Furthermore, incubation of eosinophils from normal donors with IL-5 (optimal concentration 10(-9) M), significantly enhanced the subsequent migrational responses to both IL-8 (10(-8) M, P < 0.01) and PAF (10(-8) M, P < 0.05). Therefore, the increased responsiveness of eosinophils from eosinophilic subjects may reflect in vivo priming by IL-5 and this phenomenon may contribute partly to the mechanism(s) by which eosinophils preferentially accumulate at sites of allergic inflammation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 10779297     DOI: 10.1111/j.1365-2222.1993.tb00295.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  16 in total

1.  The antiprotease SPINK7 serves as an inhibitory checkpoint for esophageal epithelial inflammatory responses.

Authors:  Nurit P Azouz; Mario A Ynga-Durand; Julie M Caldwell; Ayushi Jain; Mark Rochman; Demetria M Fischesser; Leanne M Ray; Mary C Bedard; Melissa K Mingler; Carmy Forney; Matthew Eilerman; Jonathan T Kuhl; Hua He; Jocelyn M Biagini Myers; Vincent A Mukkada; Philip E Putnam; Gurjit K Khurana Hershey; Leah C Kottyan; Ting Wen; Lisa J Martin; Marc E Rothenberg
Journal:  Sci Transl Med       Date:  2018-06-06       Impact factor: 17.956

2.  Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody.

Authors:  H Heath; S Qin; P Rao; L Wu; G LaRosa; N Kassam; P D Ponath; C R Mackay
Journal:  J Clin Invest       Date:  1997-01-15       Impact factor: 14.808

3.  Induction of tumor necrosis factor alpha and interleukin-8 gene expression in bronchial epithelial cells by toxic shock syndrome toxin 1.

Authors:  V Aubert; D Schneeberger; A Sauty; J Winter; P Sperisen; J D Aubert; F Spertini
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

4.  Priming of eosinophils by GM-CSF is mediated by protein kinase CbetaII-phosphorylated L-plastin.

Authors:  Konrad Pazdrak; Travis W Young; Christof Straub; Susan Stafford; Alexander Kurosky
Journal:  J Immunol       Date:  2011-04-27       Impact factor: 5.422

Review 5.  House dust mite interactions with airway epithelium: role in allergic airway inflammation.

Authors:  Vivek D Gandhi; Courtney Davidson; Muhammad Asaduzzaman; Drew Nahirney; Harissios Vliagoftis
Journal:  Curr Allergy Asthma Rep       Date:  2013-06       Impact factor: 4.806

6.  Inhibition by new glucocorticoid antedrugs [16α, 17α-d] isoxazoline and [16α, 17α-d]-3'-hydroxy-iminoformyl isoxazoline derivatives of chemotaxis and CCL26, CCL11, IL-8, and RANTES secretion.

Authors:  Younes J Errahali; Leeshawn D Thomas; Thomas C S Keller; Henry J Lee
Journal:  J Interferon Cytokine Res       Date:  2013-05-16       Impact factor: 2.607

7.  Allergen-induced increases in IL-5 receptor alpha-subunit expression on bone marrow-derived CD34+ cells from asthmatic subjects. A novel marker of progenitor cell commitment towards eosinophilic differentiation.

Authors:  R Sehmi; L J Wood; R Watson; R Foley; Q Hamid; P M O'Byrne; J A Denburg
Journal:  J Clin Invest       Date:  1997-11-15       Impact factor: 14.808

8.  Allergen-induced fluctuation in CC chemokine receptor 3 expression on bone marrow CD34+ cells from asthmatic subjects: significance for mobilization of haemopoietic progenitor cells in allergic inflammation.

Authors:  Roma Sehmi; Sandra Dorman; Adrian Baatjes; Rick Watson; Ronan Foley; Sun Ying; Douglas S Robinson; A Barry Kay; Paul M O'Byrne; Judah A Denburg
Journal:  Immunology       Date:  2003-08       Impact factor: 7.397

9.  Rhinovirus-Infected Epithelial Cells Produce More IL-8 and RANTES Compared With Other Respiratory Viruses.

Authors:  Yoon Hong Chun; Ju Young Park; Huisu Lee; Hyun Sook Kim; Sulmui Won; Hyun Jung Joe; Woo Jin Chung; Jong-Seo Yoon; Hyun Hee Kim; Jin Tack Kim; Joon Sung Lee
Journal:  Allergy Asthma Immunol Res       Date:  2013-05-27       Impact factor: 5.764

10.  Interleukin-5 modulates interleukin-8 secretion in eosinophilic inflammation.

Authors:  L H Faccioli; A I Medeiros; A Malheiro; R C Pietro; A Januário; B B Vargaftig
Journal:  Mediators Inflamm       Date:  1998       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.